Clinical Trial Update: Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype [Phase 3]

View source ↗

Summary

Phase 3 placebo-controlled study of depemokimab (GSK3511294) in adults with severe asthma with an eosinophilic phenotype has completed and posted results on 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Depemokimab (depemokimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2024-12-17